Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA2 in resected EGFR-mutated stage IA2-IA3 non-small cell lung cancer
jRCT2031210628Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib with Placebo (2 arms). Primary endpoint: Disease-Free Survival in high-risk stratum. Started Mar 2022; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210628.